Health Canada has approved Swedish Orphan Biovitrum’s (Sobi) Orfadin (nitisinone) capsules to treat hereditary tyrosinaemia type 1 (HT-1) disease in combination with a dietary restriction of tyrosine and phenylalanine.

HT-1 may result in liver and kidney complications and in most cases could prove fatal if not treated.

Symptoms arise within the initial six months of the child's life in the common form of the disease.

Following the approval, Orfadin capsules will now be available in Canada in 2mg, 5mg, 10mg and 20mg dosing options.

The 20mg dosage option will allow patients to take fewer pills per day.

Sobi Canada vice-president and general manager Bob McLay said: “Sobi has been committed to supporting the HT-1 community globally for more than two decades, and we were the first to develop this treatment and make it available in Canada through Health Canada’s Special Access Programme.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"This approval is an exciting moment for Sobi, as we continue to develop impactful therapies that meet the needs of patients and healthcare professionals."

“This approval is an exciting moment for Sobi, as we continue to develop impactful therapies that meet the needs of patients and healthcare professionals.”

Prior to the availability of Orfadin capsules, the survival rate in HT-1 was 29% after two years for children who developed symptoms before two months of age.

After the introduction of the capsules, the survival rate increased to 93%.

Orfadin is also approved in the US and Europe to treat patients with confirmed diagnosis of HT-1.

People with HT-1 have problems breaking down an amino acid called tyrosine and about 1,000 people worldwide are identified as living with HT-1.

Orfadin (nitisinone) works by blocking the breakdown of tyrosine and therefore reducing the amount of toxic tyrosine by-products in the body.